title: Fibrous and fibrohistiocytic neoplasms: an update.
abstract: Important advances in fibroblastic and fibrohistiocytic tumors relevant to dermatologists and dermatopathologists include (1) recognition that myxofibrosarcoma is a distinct entity that frequently arises in skin; (2) CD10 is sensitive but not specific atypical fibroxanthoma; (3) neurothekeomas lacking S100 expression are probably fibrohistiocytic/fibroblastic tumors, whereas S100+ myxoid variants are better classified as nerve sheath myxomas; (4) the recognition of a primary cutaneous variant of solitary fibrous tumor; (5) thelimitations of b-catenin immunohistochemistry in desmoid tumors; and (6) the prognostic utility of clinical and histopathologic variables in dermatofibrosarcoma protuberans, and the effects of imatinib mesylate therapy.
authors.affiliation: Department of Pathology, Penn State Hershey Medical Center, 500 University Drive, Hershey, PA 17033, USA. lclarke@hmc.psu.edu
authors.forename: Loren E
authors.initials: LE
authors.lastname: Clarke
mesh_terms: D018952:Antigens, CD34 / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D018223:Dermatofibrosarcoma / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D018221:Fibromatosis, Abdominal / Q000378:metabolism; D051677:Histiocytoma, Malignant Fibrous / Q000473:pathology*; D006801:Humans; D000068877:Imatinib Mesylate; D009236:Myxosarcoma / Q000473:pathology*; D015260:Neprilysin / Q000378:metabolism; D018321:Neurothekeoma / Q000473:pathology*; D015514:Oncogene Proteins, Fusion / Q000378:metabolism; D010879:Piperazines / Q000627:therapeutic use; D011379:Prognosis; D011743:Pyrimidines / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000378:metabolism / Q000473:pathology*; D054364:Solitary Fibrous Tumors / Q000378:metabolism / Q000473:pathology; D051176:beta Catenin / Q000378:metabolism
chemical_list: D018952:Antigens, CD34; D000970:Antineoplastic Agents; D001549:Benzamides; C120892:COLIA1-PDGFB fusion protein, human; D015514:Oncogene Proteins, Fusion; D010879:Piperazines; D011743:Pyrimidines; D051176:beta Catenin; D000068877:Imatinib Mesylate; D015260:Neprilysin